Letters Drug payments and regional prescribing

Authors’ reply to Ramachandran

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i5255 (Published 29 September 2016) Cite this as: BMJ 2016;354:i5255
  1. William Fleischman, clinical scholar1,
  2. Joseph S Ross, associate professor2,
  3. Shantanu Agrawal, deputy administrator3
  1. 1Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, 333 Cedar Street, SHM-IE 61, New Haven, CT 06510, USA
  2. 2Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA
  3. 3Center for Medicare and Medicaid Services, Department of Health and Human Services, Washington, DC, USA
  1. wf3{at}buffalo.edu

Prompted by the recently proposed US amendment S.2978 to exempt from mandatory reporting through the Open Payments program any payments from drug manufacturers to physicians related to physician education,1 Ramachandran asks whether we conducted analyses examining the association between prescribing and any payments related to educational materials.2 3

In response, we performed a subgroup analysis focused on payments for continuing medical education (CME) speaker fees and for educational materials, including journal articles and …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe